1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. RemeGen Co., Ltd.
  6. Summary
    9995   CNE1000048G6

REMEGEN CO., LTD.

(9995)
  Report
Delayed Hong Kong Stock Exchange  -  04:08 2022-06-30 am EDT
43.95 HKD   +5.90%
05/05RemeGen Co., Ltd. Approves Appointment of Chen Yunjin as Independent Non-Executive Director
CI
04/28RemeGen Widens Q1 Loss as R&D, Selling Expenses Balloon
MT
04/27RemeGen Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Hong Kong Stock Exchange
06/24/2022 06/27/2022 06/28/2022 06/29/2022 06/30/2022 Date
44.45(c) 43.8(c) 44.95(c) 41.5(c) 43.95(c) Last
4 081 900 3 238 673 1 767 593 2 102 260 1 745 448 Volume
+10.30% -1.46% +2.63% -7.68% +5.90% Change
More quotes
Estimated financial data (e)
Sales 2022 951 M 142 M 142 M
Net income 2022 -975 M -146 M -146 M
Net cash position 2022 2 331 M 348 M 348 M
P/E ratio 2022 -19,7x
Yield 2022 -
Sales 2023 2 121 M 317 M 317 M
Net income 2023 -285 M -42,6 M -42,6 M
Net cash position 2023 1 600 M 239 M 239 M
P/E ratio 2023 -67,4x
Yield 2023 -
Capitalization 24 027 M 3 587 M 3 586 M
EV / Sales 2022 22,8x
EV / Sales 2023 10,6x
Nbr of Employees 2 121
Free-Float 48,7%
More Financials
Company
RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of innovative biopharmaceuticals. The Company is mainly engaged in the discovery, development and commercialization of therapeutic antibody drugs such as antibody drug conjugates (ADCs), antibody fusion proteins, monoclonal antibodies and bispecific antibodies. The Company's main products include tetacept (RC18),... 
More about the company
Ratings of RemeGen Co., Ltd.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about REMEGEN CO., LTD.
05/05RemeGen Co., Ltd. Approves Appointment of Chen Yunjin as Independent Non-Executive Dire..
CI
04/28RemeGen Widens Q1 Loss as R&D, Selling Expenses Balloon
MT
04/27RemeGen Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
04/12RemeGen Co., Ltd. Announces Executive Changes
CI
04/11UBS Upgrades RemeGen to Buy From Neutral, Adjusts Price Target to HK$75.03 From HK$108
MT
03/31RemeGen Lists in Shanghai's STAR Market
MT
03/22RemeGen Prices Shanghai IPO to Raise $410 Million
MT
02/20RemeGen Turns to Profit in 2021 on Launch of Core Autoimmune, Cancer Drugs; Shares Rise..
MT
02/20RemeGen Co., Ltd. Reports Earnings Results for the Fourth Quarter Ended December 31, 20..
CI
01/25Remegen's Telitacicept Demonstrates Positive Results in Phase II Trial in Treatment of ..
CI
01/24RemeGen Completes Phase 2 Trial of Sjögren's Syndrome Treatment in China
MT
01/24RemeGen Co., Ltd. Completes the Phase II Clinical Study for Telitacicept to Treat Patie..
CI
01/12Hong Kong Stocks Jump to Seven-Week High; RemeGen Climbs 9% on Shanghai IPO Approval
MT
01/12Chinese Regulator Approves RemeGen's Shanghai IPO Application; Shares Jump 9%
MT
01/05Chinese Regulators Grant Conditional Marketing Approval to Remegen's Urothelial Carcino..
MT
More news
News in other languages on REMEGEN CO., LTD.
05/05RemeGen Co., Ltd. approuve la nomination de Chen Yunjin en tant que directeur non exécu..
04/28RemeGen creuse sa perte au 1er trimestre en raison de l'augmentation des frais de R&D e..
04/27RemeGen Co., Ltd. annonce ses résultats pour le premier trimestre clos le 31 mars 2022
04/12RemeGen Co., Ltd. annonce des changements de direction
02/20RemeGen réalise des bénéfices en 2021 grâce au lancement de médicaments de base contre ..
More news
Analyst Recommendations on REMEGEN CO., LTD.
More recommendations
Chart REMEGEN CO., LTD.
Duration : Period :
RemeGen Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REMEGEN CO., LTD.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 14
Last Close Price 37,52 CNY
Average target price 60,61 CNY
Spread / Average Target 61,6%
EPS Revisions
Managers and Directors
Jian Min Fang CEO, Executive Director & Chief Scientific Officer
Dao Tian Fu President
Jia Li Chief Financial Officer & Joint Secretary
Weidong Wang Chairman
Ruyi He Executive Director & Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
REMEGEN CO., LTD.-43.58%3 509
GILEAD SCIENCES, INC.-14.87%77 529
VERTEX PHARMACEUTICALS28.32%72 069
REGENERON PHARMACEUTICALS, INC.-6.40%63 692
WUXI APPTEC CO., LTD.-13.31%45 031
BIONTECH SE-42.16%36 234